CL2015002593A1 - Formas cristalinas de inhibidores de tirosin quinasa y sus sales - Google Patents
Formas cristalinas de inhibidores de tirosin quinasa y sus salesInfo
- Publication number
- CL2015002593A1 CL2015002593A1 CL2015002593A CL2015002593A CL2015002593A1 CL 2015002593 A1 CL2015002593 A1 CL 2015002593A1 CL 2015002593 A CL2015002593 A CL 2015002593A CL 2015002593 A CL2015002593 A CL 2015002593A CL 2015002593 A1 CL2015002593 A1 CL 2015002593A1
- Authority
- CL
- Chile
- Prior art keywords
- salts
- tyrosine kinase
- kinase inhibitors
- crystalline forms
- crystal
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000013078 crystal Substances 0.000 abstract 2
- -1 AMINO Chemical class 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 abstract 1
- 235000010234 sodium benzoate Nutrition 0.000 abstract 1
- 239000004299 sodium benzoate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801112P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015002593A1 true CL2015002593A1 (es) | 2016-08-19 |
Family
ID=51529961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015002593A CL2015002593A1 (es) | 2013-03-15 | 2015-09-10 | Formas cristalinas de inhibidores de tirosin quinasa y sus sales |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US8999992B2 (enExample) |
| EP (1) | EP2970148A4 (enExample) |
| JP (1) | JP2016513704A (enExample) |
| KR (1) | KR20150142688A (enExample) |
| CN (1) | CN105377821A (enExample) |
| AU (1) | AU2014239254B2 (enExample) |
| BR (1) | BR112015022631A2 (enExample) |
| CA (1) | CA2904403A1 (enExample) |
| CL (1) | CL2015002593A1 (enExample) |
| CR (1) | CR20150560A (enExample) |
| EA (1) | EA201591684A1 (enExample) |
| GT (1) | GT201500292A (enExample) |
| HK (1) | HK1220193A1 (enExample) |
| MX (1) | MX2015012403A (enExample) |
| NI (1) | NI201500139A (enExample) |
| PE (1) | PE20151884A1 (enExample) |
| PH (1) | PH12015502110A1 (enExample) |
| SG (2) | SG10201707484UA (enExample) |
| SV (1) | SV2015005074A (enExample) |
| TN (1) | TN2015000407A1 (enExample) |
| UA (1) | UA116466C2 (enExample) |
| WO (1) | WO2014152663A1 (enExample) |
| ZA (1) | ZA201507154B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106336400A (zh) | 2008-12-08 | 2017-01-18 | 萌蒂制药国际有限公司 | 酪氨酸激酶蛋白受体拮抗剂 |
| US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
| US10301271B2 (en) * | 2014-09-17 | 2019-05-28 | Purdue Pharma L.P. | Crystalline forms of tyrosine kinase inhibitors and their salts |
| US20180370926A1 (en) * | 2015-08-07 | 2018-12-27 | Purdue Pharma L.P. | Process of preparing tyrosine kinase inhibitor |
| AU2018350980C1 (en) | 2017-10-18 | 2024-12-12 | Incyte Corporation | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors |
| WO2019159097A1 (en) * | 2018-02-14 | 2019-08-22 | Sun Pharmaceutical Industries Limited | Crystalline polymorphic forms of acalabrutinib |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| EP4486448A1 (en) | 2022-03-04 | 2025-01-08 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1062357A (en) * | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| US4337341A (en) * | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| RU2065438C1 (ru) | 1993-12-22 | 1996-08-20 | Институт химии природного органического сырья СО РАН | Способ получения производных 3-фенилокси-5-гидроксиантра (1,9-cd)-изоксазол-6-она |
| US6635626B1 (en) | 1997-08-25 | 2003-10-21 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
| US5998463A (en) | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
| US6476032B2 (en) | 1998-12-17 | 2002-11-05 | Wyeth | 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives |
| MXPA01012442A (es) | 1999-06-03 | 2004-09-10 | Abbott Gmbh & Co Kg | Compuestos de benzotiazinona y benzoxazinona. |
| FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| ES2275021T3 (es) | 2001-09-27 | 2007-06-01 | Smithkline Beecham Corporation | Derivados de azoxoindol como inhibidores de trk proteina quinasa para el tratamiento de cancer y dolor cronico. |
| KR20030095729A (ko) | 2002-06-14 | 2003-12-24 | 크리스탈지노믹스(주) | 2-[5-(3-카복시-4-클로로-페닐)-푸란-2-일메틸렌]-3-옥소-2,3-디하이드로-5Ｈ-티아졸로[3,2-ａ]피리미딘-6-카복실산에틸 에스테르 유도체를 포함하는 단백질 티로신포스파타제 1Ｂ 활성 억제용 약학 조성물 |
| EP1556083B1 (en) | 2002-10-08 | 2011-02-02 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering an antibody against nerve growth factor and compositions containing the same |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| IL154370A0 (en) * | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| EP1629000B1 (en) | 2003-04-16 | 2009-02-18 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
| CA2535265C (en) | 2003-08-22 | 2014-01-28 | Dendreon Corporation | Compositions and methods for the treatment of disease associated with trp-p8 expression |
| WO2008021463A2 (en) | 2006-08-15 | 2008-02-21 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| AU2005243247B2 (en) | 2004-04-07 | 2012-03-01 | Regents Of The University Of Minnesota | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| WO2006007864A1 (en) | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Treating neurodegenerative conditions |
| US7671077B2 (en) * | 2004-07-19 | 2010-03-02 | Leu-Fen Hou Lin | Neuroprotective small organic molecules, compositions and uses related thereto |
| US7718674B2 (en) | 2004-09-27 | 2010-05-18 | Bridge Pharma, Inc. | Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine |
| MX2007008771A (es) | 2005-01-19 | 2007-09-11 | Mgi Gp Inc | Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp. |
| FR2881138B1 (fr) | 2005-01-27 | 2007-03-02 | Servier Lab | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20060257337A1 (en) | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
| JP5191155B2 (ja) | 2006-03-27 | 2013-04-24 | 大塚製薬株式会社 | カルボスチリル化合物からなる医薬 |
| JP2007303392A (ja) | 2006-05-11 | 2007-11-22 | Honda Motor Co Ltd | 気体燃料内燃機関の制御装置 |
| WO2008053863A1 (en) | 2006-10-30 | 2008-05-08 | Santen Pharmaceutical Co., Ltd. | Novel compound having 1,4-benzothiazin-3-one skeleton or 3,4-dihydroquinolin-2-one skeleton |
| ES2506090T3 (es) | 2006-12-28 | 2014-10-13 | Abbvie Inc. | Inhibidores de la (ADP-ribosa) polimerasa |
| WO2009024989A2 (en) | 2007-08-17 | 2009-02-26 | Hetero Drugs Limited | A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b |
| JP5662801B2 (ja) | 2007-11-16 | 2015-02-04 | ホリンワース ファンド，エル．エル．シー． | フィルタ設計方法およびメタマテリアル構造ベースのフィルタ |
| CN106336400A (zh) * | 2008-12-08 | 2017-01-18 | 萌蒂制药国际有限公司 | 酪氨酸激酶蛋白受体拮抗剂 |
| EP2239256A1 (en) * | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
| WO2011063398A1 (en) * | 2009-11-23 | 2011-05-26 | Cylene Pharamaceuticals, Inc. | Polymorphs and salts of a kinase inhibitor |
| PH12012502495A1 (en) | 2010-06-23 | 2013-02-11 | Osi Pharmaceuticals Llc | Polymorphs of osi-906 |
| AU2012205669B2 (en) | 2011-01-10 | 2015-08-20 | Infinity Pharmaceuticals Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| US9376406B2 (en) | 2011-03-03 | 2016-06-28 | Indiana University Research And Technology Corporation | uPAR-uPA interaction inhibitors and methods for treating cancer |
| US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
| US10301271B2 (en) | 2014-09-17 | 2019-05-28 | Purdue Pharma L.P. | Crystalline forms of tyrosine kinase inhibitors and their salts |
-
2014
- 2014-03-13 US US14/208,244 patent/US8999992B2/en active Active
- 2014-03-14 MX MX2015012403A patent/MX2015012403A/es unknown
- 2014-03-14 BR BR112015022631A patent/BR112015022631A2/pt not_active IP Right Cessation
- 2014-03-14 PE PE2015002014A patent/PE20151884A1/es not_active Application Discontinuation
- 2014-03-14 EP EP14770743.4A patent/EP2970148A4/en not_active Withdrawn
- 2014-03-14 EA EA201591684A patent/EA201591684A1/ru unknown
- 2014-03-14 SG SG10201707484UA patent/SG10201707484UA/en unknown
- 2014-03-14 HK HK16108270.6A patent/HK1220193A1/zh unknown
- 2014-03-14 CA CA2904403A patent/CA2904403A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/027591 patent/WO2014152663A1/en not_active Ceased
- 2014-03-14 CN CN201480015906.9A patent/CN105377821A/zh active Pending
- 2014-03-14 CR CR20150560A patent/CR20150560A/es unknown
- 2014-03-14 AU AU2014239254A patent/AU2014239254B2/en not_active Expired - Fee Related
- 2014-03-14 JP JP2016502487A patent/JP2016513704A/ja active Pending
- 2014-03-14 SG SG11201507516XA patent/SG11201507516XA/en unknown
- 2014-03-14 UA UAA201509781A patent/UA116466C2/uk unknown
- 2014-03-14 US US14/772,264 patent/US9718794B2/en active Active
- 2014-03-14 KR KR1020157029442A patent/KR20150142688A/ko not_active Withdrawn
-
2015
- 2015-03-02 US US14/635,635 patent/US9388146B2/en active Active
- 2015-09-10 CL CL2015002593A patent/CL2015002593A1/es unknown
- 2015-09-10 TN TN2015000407A patent/TN2015000407A1/en unknown
- 2015-09-11 NI NI201500139A patent/NI201500139A/es unknown
- 2015-09-14 PH PH12015502110A patent/PH12015502110A1/en unknown
- 2015-09-14 GT GT201500292A patent/GT201500292A/es unknown
- 2015-09-14 SV SV2015005074A patent/SV2015005074A/es unknown
- 2015-09-28 ZA ZA2015/07154A patent/ZA201507154B/en unknown
-
2016
- 2016-06-17 US US15/185,754 patent/US9993473B2/en active Active
-
2017
- 2017-07-13 US US15/648,527 patent/US10124002B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38221A (es) | Inhibidores de proteínas ras con g12c mutantes | |
| CL2018000374A1 (es) | Sales de un inhibidor de lsd1 | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| MX2017013797A (es) | Inhibidor de janus quinasa. | |
| AR111469A1 (es) | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma | |
| CU20160149A7 (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
| NZ710270A (en) | Pyridone amides as modulators of sodium channels | |
| MX2016012097A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer. | |
| EA201692356A1 (ru) | Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида | |
| PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
| MX368833B (es) | Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor. | |
| SV2015005074A (es) | Formas cristalinas de inhibidores de tirosina cinasa y sus sales | |
| CO2019012571A2 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| EA201890331A1 (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
| PE20160801A1 (es) | Derivados de heterobicicloaril como inhibidores rorc2 y metodos de uso de los mismos | |
| DOP2015000170A (es) | Compuestos químicos | |
| EA201692470A1 (ru) | Фармацевтические комбинации | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| CL2020001009A1 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos. | |
| MX2017003439A (es) | Formas cristalinas de inhibidores de tirosina cinasa y sus sales. | |
| EA201892539A1 (ru) | Пиридинильные производные, фармацевтические композиции и их применение в качестве ингибиторов аос3 | |
| EA201600123A1 (ru) | Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона | |
| BR112018016396A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratar um distúrbio | |
| AR105400A1 (es) | Inhibidores de jak1 | |
| EA201990480A1 (ru) | Комбинация обратных агонистов гистамин-3 рецептора с ингибиторами ацетилхолинэстеразы |